Evidence map›Paper›PMID 27428710›Full record

Trial reportArthritis & rheumatology (Hoboken, N.J.)2017

Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Ruth J Pepper, Juliana B Draibe, Ben Caplin, Fernando C Fervenza, Gary S Hoffman, Cees G M Kallenberg, Carol A Langford, Paul A Monach, Philip Seo, Robert Spiera and 7 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Interventions for renal vasculitis in adults.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Biomarkers in Primary Systemic Vasculitides: Narrative Review.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 3 countries.

Ruth J PepperUniversity College London Centre for Nephrology, Royal Free Hospital, London, UK.
Juliana B DraibeUniversity College London Centre for Nephrology, Royal Free Hospital, London, UK.
Ben CaplinUniversity College London Centre for Nephrology, Royal Free Hospital, London, UK.
Fernando C FervenzaMayo Clinic, Rochester, Minnesota.
Gary S HoffmanCleveland Clinic Foundation, Cleveland, Ohio.
Cees G M KallenbergUniversity of Groningen, Groningen, The Netherlands.
Carol A LangfordCleveland Clinic Foundation, Cleveland, Ohio.
Paul A MonachBoston University, Boston, Massachusetts.
Philip SeoJohns Hopkins University, Baltimore, Maryland.
Robert SpieraHospital for Special Surgery, New York, New York.
E William St ClairDuke University Medical Center, Durham, North Carolina.
Nadia K TchaoImmune Tolerance Network, San Francisco, California.
John H StoneMassachusetts General Hospital, Boston.
Ulrich SpecksMayo Clinic, Rochester, Minnesota.
Peter A MerkelUniversity of Pennsylvania, Philadelphia.
Alan D SalamaUniversity College London Centre for Nephrology, Royal Free Hospital, London, UK.
RAVE-Immune Tolerance Network Research Group
University College London · GBCleveland Clinic · USMayo Clinic · USBoston University · USDuke Medical Center · USHospital for Special Surgery · USImmune Tolerance Network · USJohns Hopkins University · USMassachusetts General Hospital · USPhiladelphia University · USThe Royal Free Hospital · GBUniversity of Groningen · NL

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
IMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–
NCATS NIH HHS UL1 TR000439NIAID NIH HHS N01 AI015416
6 · The paper itself

Abstract

objectiveS100A8/A9 (calprotectin) has shown promise as a biomarker for predicting relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This study was undertaken to investigate serum S100A8/A9 level as a biomarker for predicting future relapse in a large cohort of patients with severe AAV.

methodsSerum levels of S100A8/A9 were measured at baseline and months 1, 2, and 6 following treatment initiation in 144 patients in the Rituximab in ANCA-Associated Vasculitis trial (cyclophosphamide/azathioprine versus rituximab [RTX] for induction of remission) in whom complete remission was attained.

resultsPatients were divided into 4 groups: proteinase 3 (PR3)-ANCA with relapse (n = 37), PR3-ANCA without relapse (n = 56), myeloperoxidase (MPO)-ANCA with relapse (n = 6), and MPO-ANCA without relapse (n = 45). Serum S100A8/A9 level decreased in all groups during the first 6 months of treatment. The percentage reduction from baseline to month 2 was significantly different between patients who experienced a relapse and those who did not in the PR3-ANCA group (P = 0.046). A significantly higher risk of relapse was associated with an increase in S100A8/A9 level between baseline and month 2 (P = 0.0043) and baseline and month 6 (P = 0.0029). Subgroup analysis demonstrated that patients treated with RTX who had increased levels of S100A8/A9 were at greatest risk of future relapse (P = 0.028).

conclusionAn increase in serum S100A8/A9 level by month 2 or 6 compared to baseline identifies a subgroup of PR3-ANCA patients treated with RTX who are at higher risk of relapse by 18 months. Since RTX is increasingly used for remission induction in PR3-ANCA-positive patients experiencing a relapse, S100A8/A9 level may assist in identifying those patients requiring more intensive or prolonged treatment.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisBiomarkersDouble-Blind MethodFemaleHumansImmunologic FactorsLeukocyte L1 Antigen ComplexMaleMiddle AgedMyeloblastinPredictive Value of TestsAntibodies, Antineutrophil CytoplasmicBiomarkersImmunologic FactorsLeukocyte L1 Antigen ComplexMyeloblastinRituximab

Identifiers

PMID27428710
PMCPMC5839649
OpenAlexW2574098875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.